Browse News
Filter News
Found 16,725 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Autoimmune Hepatitis Diagnosis and Treatment Market Size Set to Soar USD 19.15 Billion by 2032
4/23/2024
The global autoimmune hepatitis diagnosis and treatment market size is projected to increase from USD 14.03 billion in 2023 to approximately USD 19.15 billion by 2032. This growth, at a CAGR of 3.3% from 2023 to 2032
-
Lipid Nanoparticles (LNPs) CDMO Market to Reach USD 518.2 Million with a CAGR of 14.10% from 2024-2031
4/23/2024
Global Lipid Nanoparticles (LNPs) CDMO Market in terms of revenue was predicted to be worth $182.0 Mn in 2023 and is poised to reach 518.2 Mn by 2031, increasing at a CAGR of 14.10% from 2024 to 2031.
-
Primary Cell Culture Market Size to Worth Around USD 21.51 Billion by 2033
4/22/2024
According to Precedence Research, the primary cell culture market size was valued at USD 7.03 billion in 2023 and is expected to be worth around USD 21.51 billion by 2033, expanding at a CAGR of 11.81% from 2024 to 2033.
-
Synthetic Biology Industry is Rising Rapidly Up to USD 80.17 Bn by 2033
4/22/2024
The global synthetic biology market size was worth around USD 14.09 billion in 2024 and is predicted to grow around USD 80.17 billion by 2033 with a compound annual growth rate (CAGR) of roughly 18.99% between 2024 and 2033 According to a new report by Nova One Advisor.
-
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4/22/2024
Legend Biotech Corporation announced today that the European Commission (EC) has granted approval of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), have demonstrated disease progression on the last therapy and are refractory to lenalidomide.
-
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
4/22/2024
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections.
-
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
4/22/2024
Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19.
-
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award
4/19/2024
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C.
-
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
4/18/2024
TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility.
-
Red Biotechnology Market Size, CAGR, Trends, Report 2024 to 2033
4/18/2024
According to Vision Research Reports, the global red biotechnology market size was estimated at around USD 492.74 billion in 2023
-
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
4/18/2024
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces receipt of clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 1 clinical trial with a seasonal COVID-19 booster vaccine.
-
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
4/18/2024
AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA).
-
Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza
4/18/2024
Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows, chickens and one person in Texas.
-
Soligenix Announces Pricing of $4.75 Million Public Offering
4/18/2024
Soligenix, Inc. announced the pricing of its public offering of 11,875,000 shares of common stock and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses.
-
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
4/18/2024
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.
-
Quebec's INESSS recommends BEYFORTUS for the prevention of RSV for all infants 8 months of age and younger(1)
4/18/2024
BEYFORTUS ® (nirsevimab) is the first long-acting antibody approved in Canada for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants through their first RSV season.
-
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
4/18/2024
CureVac N.V. will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024.
-
National Comprehensive Cancer Network Awards Champions for Excellence and Outstanding Contributions in Cancer Care
4/17/2024
The National Comprehensive Cancer Network® is announcing 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN's mission to help all people with cancer to live better lives.